Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques LeLorier

Showing results (81-90 of 97) with videos related to

Pageof 10
Sort By:
Circulation. Cardiovascular Quality and Outcomes|December 16, 2010
Willingness to pay to eliminate the risk of restenosis following percutaneous coronary intervention: a contingent valuationJason R Guertin, Aihua Liu, Michal Abrahamowicz, et al.
The Canadian Journal of Cardiology|January 9, 2003
Practical considerations for the use of nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors in hypertension and kidney diseaseJacques LeLorier, Claire Bombardier, Ellen Burgess, et al.
Current Medical Research and Opinion|September 21, 2016
Maximal expected benefits from lowering cholesterol in primary prevention for a high-risk populationFiorella Fanton-Aita, Alexis Matteau, Ange Christelle Iliza, et al.
Molecular Diagnosis & Therapy|April 14, 2018
A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular PreventionDominic Mitchell, Jason R Guertin, Anick Dubois, et al.
Pharmacogenomics|October 11, 2016
A model to assess the cost-effectiveness of pharmacogenomics tests in chronic heart failure: the case of ivabradineAnge C Iliza, Alexis Matteau, Jason R Guertin, et al.
Health Policy (Amsterdam, Netherlands)|June 16, 2007
The effects of coxib formulary restrictions on analgesic use and cost: regional evidence from CanadaDeborah A Marshall, Donald J Willison, Paul Grootendorst, et al.
Circulation. Cardiovascular Quality and Outcomes|December 25, 2009
The impact of a multidisciplinary information technology-supported program on blood pressure control in primary careStéphane Rinfret, Marie-Thérèse Lussier, Anthony Peirce, et al.
Journal of Neurology|September 1, 2012
Future MS care: a consensus statement of the MS in the 21st Century Steering GroupPeter Rieckmann, Alexey Boyko, Diego Centonze, et al.
Nephron. Clinical Practice|December 4, 2009
Vascular access-related bloodstream infections in First Nations, community and teaching Canadian dialysis units, and other centre-level predictorsJean-Philippe Lafrance, Sameena Iqbal, Jacques Lelorier, et al.
Hospital Pediatrics|May 2, 2018
Long-term Mortality After Acute Kidney Injury in the Pediatric ICUErin Hessey, Geneviève Morissette, Jacques Lacroix, et al.
Pageof 10

Showing results (81-90 of 97) with videos related to

Sort By:
Pageof 10
Circulation. Cardiovascular Quality and Outcomes|December 16, 2010
Willingness to pay to eliminate the risk of restenosis following percutaneous coronary intervention: a contingent valuationJason R Guertin, Aihua Liu, Michal Abrahamowicz, et al.
The Canadian Journal of Cardiology|January 9, 2003
Practical considerations for the use of nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors in hypertension and kidney diseaseJacques LeLorier, Claire Bombardier, Ellen Burgess, et al.
Current Medical Research and Opinion|September 21, 2016
Maximal expected benefits from lowering cholesterol in primary prevention for a high-risk populationFiorella Fanton-Aita, Alexis Matteau, Ange Christelle Iliza, et al.
Molecular Diagnosis & Therapy|April 14, 2018
A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular PreventionDominic Mitchell, Jason R Guertin, Anick Dubois, et al.
Pharmacogenomics|October 11, 2016
A model to assess the cost-effectiveness of pharmacogenomics tests in chronic heart failure: the case of ivabradineAnge C Iliza, Alexis Matteau, Jason R Guertin, et al.
Health Policy (Amsterdam, Netherlands)|June 16, 2007
The effects of coxib formulary restrictions on analgesic use and cost: regional evidence from CanadaDeborah A Marshall, Donald J Willison, Paul Grootendorst, et al.
Circulation. Cardiovascular Quality and Outcomes|December 25, 2009
The impact of a multidisciplinary information technology-supported program on blood pressure control in primary careStéphane Rinfret, Marie-Thérèse Lussier, Anthony Peirce, et al.
Journal of Neurology|September 1, 2012
Future MS care: a consensus statement of the MS in the 21st Century Steering GroupPeter Rieckmann, Alexey Boyko, Diego Centonze, et al.
Nephron. Clinical Practice|December 4, 2009
Vascular access-related bloodstream infections in First Nations, community and teaching Canadian dialysis units, and other centre-level predictorsJean-Philippe Lafrance, Sameena Iqbal, Jacques Lelorier, et al.
Hospital Pediatrics|May 2, 2018
Long-term Mortality After Acute Kidney Injury in the Pediatric ICUErin Hessey, Geneviève Morissette, Jacques Lacroix, et al.
Pageof 10